Related Experiment Video
Updated: Jun 11, 2026
04:44
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Interstitial lung disease in rheumatoid arthritis
1Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, BST S707, 3500 Terrace Street, Pittsburgh, PA 15261, USA. ascher@pitt.edu
Current Rheumatology Reports
|July 15, 2010
Summary
Rheumatoid arthritis (RA) can cause interstitial lung disease (ILD), a serious complication. Developing biomarkers is crucial for predicting RA-ILD progression and guiding treatment with immunomodulators and antifibrotic agents.
Area of Science:
- Rheumatology
- Pulmonology
- Immunology
Background:
- Rheumatoid arthritis (RA) is a prevalent systemic autoimmune disease affecting 1-2% of US adults.
- While primarily targeting joints, RA frequently causes extra-articular manifestations, notably lung involvement.
- Interstitial lung disease (ILD) is a severe pulmonary complication of RA, ranging from mild inflammation to advanced fibrosis.
Purpose of the Study:
- To highlight the significant impact of RA-associated ILD (RA-ILD) on patient morbidity and mortality.
- To underscore the need for improved biomarker development to predict RA-ILD progression.
- To guide the application and timing of therapeutic strategies for RA-ILD.
Main Methods:
- Review of recent epidemiological and pathogenetic insights into RA-ILD.
- Analysis of current understanding of RA-ILD complexity and progression predictors.
- Identification of the need for molecular signatures for targeted therapies.
Main Results:
- RA-ILD is a major cause of morbidity and mortality in rheumatoid arthritis patients.
- Current understanding of RA-ILD pathogenesis and progression predictors remains incomplete.
- There is a critical need for advanced biomarker development for RA-ILD.
Conclusions:
- Clinically significant RA-ILD poses a substantial threat to patients with rheumatoid arthritis.
- Improved molecular signatures are essential for predicting disease course and optimizing treatment.
- Future therapeutic strategies will benefit from precise biomarker-guided application of immunomodulators and antifibrotic agents.
Related Concept Videos
01:23Rheumatic Heart Disease I: Introduction
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:19Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations
Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...